Impact of renal function on the prognosis of patients receiving Atezolizumab / Bevacizumab combination therapy and Lenvatinib monotherapy for unresectable hepatocellular carcinoma.

In patients receiving AB and LEN therapy, baseline proteinuria was associated with OS. Renal function deterioration without proteinuria was associated with a poor prognosis in AB therapy. Excessive salt intake, pre-existing atherosclerotic disease, and drug with a high risk of renal dysfunction were risk factors for renal deterioration.